ERBB2 and breast cancer: We showed a significant gain (p < 0.0001) in the expression of PDK1 and PDK3 in TNBC versus non-TNBC and in basal-like breast cancers relative to other subtypes such as luminal A, luminal B and HER2-enriched breast cancers (Figure 1a–c).